Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091819 · ClinicalTrials.gov registry record · Phase 3
Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
A Phase 3 study, sponsored by Cumberland Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 862
- Enrollment target
NCT00091819: Completed Phase 3 study, sponsored by Cumberland Pharmaceuticals.
NCT00091819 is a Phase 3 study that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 862 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00091819, a Phase 3 study, has completed, sponsored by Cumberland Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 862 participants
- Enrollment target
Study Summary
Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
Primary Outcome
The Clinical Response for each patient was determined by the investigator by assessing a patient's clinical signs and symptoms at the specified evaluation compared with the Baseline evaluation. Cure: resolution of signs and symptoms associated with the skin infection present at study admission such that no further antibiotic therapy was necessary; Not Cured: inadequate response to study therapy; Indeterminate: unable to determine outcome.
Interventions
- DRUG Vancomycin
- DRUG Telavancin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 862 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
What the finished NCT00091819 record still lists
NCT00091819 is an interventional study that assigns participants to a tested intervention. The registered 862 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% higher).
The record links to 0 conditions, and to 2 interventions - of which Vancomycin is the first listed.
NCT00091819 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00091819 about?
NCT00091819 is a clinical study titled "Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus". Study 0017 compares the safety and effectiveness of an investigational drug, telavancin, and an approved drug, vancomycin, for the treatment of complicated skin and skin structure infections.
What is the current status of trial NCT00091819?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 862 participants. The study started on 2005-01. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00091819?
The interventions under investigation include: Vancomycin (DRUG), Telavancin (DRUG).
Who is sponsoring clinical trial NCT00091819?
This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00091819's enrollment target sits among peer trials
862 380th of 2000 higher than 1,621 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05914116 · 862 participants · Phase 1
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- NCT06256588 · 864 participants · Phase 3
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- NCT06527794 · 864 participants · NA
Remote Hypertension Management for Black Patients
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia